目的 研究老年人胃肠道间质瘤(gastrointestinal stromal tumors ,GIST)c-kit和PDGFRa基因突变及其临床病理学意义。方法 采用免疫组织化学技术并结合PCR扩增和测序技术,检测医院病理科2005-01至2017-12存档的老年GIST患者标本共79例,统计并分析免疫表型特征及c-kit和PDGFRa基因突变情况。结果 79例老年GIST患者,高发年龄为65~75岁,c-kit基因突变率为88.6%(70/79),PDGFRa基因突变率为8.9%(7/79),野生型GIST2.5%(2/79);其中c-kit基因11号外显子突变为最常见,占83.5%(65/77)。结论 多数老年人GIST患者携有特征性c-kit/PDGFRa基因突变,为GIST的确诊和生物靶向治疗提供了重要依据。
Abstract
Objective To investigate the gene mutation of c-kit and PDGFRa in gastrointestinal stromal tumors(GIST).Methods Immunohistochemistry, PCR amplification and sequencing were used to detect immunophenotypic characteristics and mutations of c-kit and PDGFRa genes of 79 cases of gastrointestinal stromal tumors which were documented in the Department of Pathology of our hospital between January 2005 and December 2017.Results In this study, most of the elderly patients with GIST ranged 65 to 75 in age. c-kit and/or PDGFRa gene mutations were detected in 77/79 cases, including c-kit mutation (70 cases, 88.6%), PDGFRa mutation (7 cases, 8.9%) and wild type (2 cases, 2.5%). Exon 11 mutation of c-kit genes was the most common (65/77, 82.3%).Conclusions Most of the aged patients with GIST typically carry c-kit and/or PDGFRa gene mutations, which provides molecular evidence for confirmation of the diagnosis and for targeted therapies.
关键词
老年人 /
胃肠道间质瘤 /
基因突变 /
PDGFRa /
c-kit
Key words
elderly /
gastrointestinal stromal tumor /
gene mutation /
PDGFRa /
c-kit
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Mazur M T, Clark H B. Gastric stromal tumors: reappraisal of histogenesis [J]. Am J Surg Pathol, 1983, 7: 507-519.
[2] Novelli M, Rossi S, Rodriguez J M, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumors [J]. Histopathology, 2010, 57(2): 259-270.
[3] 2013年中国胃肠道间质瘤病理诊断共识专家组. 中国胃肠道间质瘤病理诊断共识(2013年版)解读[J]. 中华病理学杂志,2015,44(1):3-8.
[4] Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998,279(5350):577-580.
[5] Heinrich M C, Corless C L, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors[J]. Science, 2003, 299(5607):708-710.
[6] Miettinen M, Wang Z F, Laota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases [J]. Am J Surg Pathol, 2009, 33(9):437-446.
[7] Liegl B A, Fletcher J A, Fletcher C D. Gastrointestinal stromal tumors [J]. Vichows Arch 2010,456(2):111-137.
[8] 沈学成,熊朝晖,赵本隆,等.腹膜后巨大胃肠外间质瘤1例[J].武警医学,2017,28(6):625-627.
[9] 吴 炼,陈道荣.胃间质瘤组织中Ki-67表达与危险度分级的关系[J].山东医药,2018,58(41):51-54.
[10] 张秀敏,林 慧,叶 青,等. 胃肠道间质瘤KIT及PDGFRA基因突变的检测及分析 [J].中国肿瘤临床,2012,3(10):660-665.
[11] 王 莉,辛英瑛,缪连生,等.CD117、DOG1表达与胃间质瘤侵袭危险度的关系[J].甘肃医药,2018,37(1):18-20.
[12] Makar R R, Waheeb S, John B, et al. Gastrointestinal stromal tumor: clinicopathological and inmmunohistochemical features [J]. Med Princ Pract, 2002, 11(1): 93-97.
[13] 王 翃,徐洪雨.胃间质瘤治疗方法的研究进展[J].国际消化病杂志,2018,38(2):89-93.
[14] Yamamoto H,Kojima A,Nagata S,et al.KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue:a clinicopathologic and genetic study of 10 cases [J].Am J Surg Pathol,2011,35(9):1287-1295.
[15] 方仕旭,林 彬,王 峰,等.胃间质瘤药物治疗的最新进展[J].医学理论与实践,2018,31(16):2391-2393.
PDF(651 KB)
